Sage Therapeutics, Inc. (SAGE) News
Filter SAGE News Items
SAGE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SAGE News Highlights
- For SAGE, its 30 day story count is now at 7.
- Over the past 23 days, the trend for SAGE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about SAGE are BEAT, HUGE and UTHR.
Latest SAGE News From Around the Web
Below are the latest news stories about SAGE THERAPEUTICS INC that investors may wish to consider to help them evaluate SAGE as an investment opportunity.
Elizabeth Barrett At Sage Therapeutics Tops Up Holding By US$51k \Even if it's not a huge purchase, we think it was good to see that Elizabeth Barrett, a Sage Therapeutics, Inc... |
Sage Therapeutics to Present at Upcoming May Investor ConferencesCAMBRIDGE, Mass., May 03, 2023--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in May: |
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue EstimatesSage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business ProgressCAMBRIDGE, Mass., May 02, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2023. |
Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to DeclineUnited Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Sage Therapeutics, Inc. (NASDAQ:SAGE) insiders placed bullish bets worth US$752k in the last 12 monthsIn the last year, multiple insiders have substantially increased their holdings of Sage Therapeutics, Inc... |
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out forSage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023CAMBRIDGE, Mass., April 18, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 2, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and discuss recent business updates. |
Sage Therapeutics to Present at the Stifel 2023 CNS DaysCAMBRIDGE, Mass., March 22, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 11:00 a.m. ET. |
Sage Therapeutics Appoints Jessica Federer to Board of DirectorsCAMBRIDGE, Mass., March 16, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors. |